Serum gets DCGI nod for Phase 2 & 3 trials
India’s apex drug regulator has allowed Pune-based Serum Institute of India to conduct late-stage — Phase 2 and 3 — human trials in India for the Oxford University Covid-19 vaccine candidate.
from Times of India https://ift.tt/2Xp9JnX
https://ift.tt/eA8V8J August 04, 2020 at 08:06AM
from Times of India https://ift.tt/2Xp9JnX
https://ift.tt/eA8V8J August 04, 2020 at 08:06AM
Comments
Post a Comment